Therapeutic,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Feb '25),Est. Status,HeavySequence,LightSequence,HeavySequence(ifbispec),LightSequence(ifbispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes,Genetics (Bispecifics delimited with semicolon),Alternative Therapeutic Names
Abagovomab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS,DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK,na,na,None,None,None,2006,2007,MUC16/CA125,Menarini,na,na,Ovarian cancer;Pancreatic cancer,,,Murine,ACA 125;ACA125;ACA-125
Abazistobart,Whole mAb,G4,Kappa,TBC,TBC,EVKLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKRLEWVATISGGGRYTYYPDTVKGRFTISRDNAKNSHYLQMNSLRAEDTAVYFCASPYGGYFDVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISNFLHWYQQKPGQAPRLLIKYASQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSNSWPHTFGQGTKVEIK,na,na,7vux:HL,None,None,2025,na,PDCD1/CD279/PD1,Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd,na,Cancer,na,,,Chimeric and Humanised,609A